What is a stock summary page? Click here for an overview.
Business Description
Entera Bio Ltd
NAICS : 541713
SIC : 2833
ISIN : IL0011429839
Description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 31.84 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 30.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39 | |||||
| 3-Year EBITDA Growth Rate | 18.4 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 19.5 | |||||
| 3-Year Book Growth Rate | -35.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.21 | |||||
| 9-Day RSI | 73.23 | |||||
| 14-Day RSI | 68.23 | |||||
| 3-1 Month Momentum % | -24.89 | |||||
| 6-1 Month Momentum % | -5.91 | |||||
| 12-1 Month Momentum % | -11.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.63 | |||||
| Quick Ratio | 7.63 | |||||
| Cash Ratio | 7.36 | |||||
| Days Sales Outstanding | 151.24 | |||||
| Days Payable | 226.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.5 | |||||
| Shareholder Yield % | -3.63 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 4.97 | |||||
| Operating Margin % | -5295.58 | |||||
| Net Margin % | -5271.27 | |||||
| FCF Margin % | -3766.85 | |||||
| ROE % | -112.74 | |||||
| ROA % | -97.02 | |||||
| ROIC % | -954.75 | |||||
| 3-Year ROIIC % | -673.42 | |||||
| ROC (Joel Greenblatt) % | -2294.16 | |||||
| ROCE % | -110.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 456 | |||||
| PB Ratio | 10.86 | |||||
| Price-to-Tangible-Book | 10.86 | |||||
| EV-to-EBIT | -9.93 | |||||
| EV-to-EBITDA | -9.98 | |||||
| EV-to-Revenue | 525.81 | |||||
| EV-to-Forward-Revenue | 379.92 | |||||
| EV-to-FCF | -14.76 | |||||
| Price-to-Net-Current-Asset-Value | 11.4 | |||||
| Price-to-Net-Cash | 12 | |||||
| Earnings Yield (Greenblatt) % | -10.07 | |||||
| FCF Yield % | -6.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entera Bio Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.181 | ||
| EPS (TTM) ($) | -0.25 | ||
| Beta | 1.68 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.15 | ||
| Volatility % | 52.03 | ||
| 14-Day RSI | 68.23 | ||
| 14-Day ATR ($) | 0.162832 | ||
| 20-Day SMA ($) | 1.826525 | ||
| 12-1 Month Momentum % | -11.62 | ||
| 52-Week Range ($) | 1.41 - 2.79 | ||
| Shares Outstanding (Mil) | 45.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Entera Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Entera Bio Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Entera Bio Ltd Frequently Asked Questions
What is Entera Bio Ltd(ENTX)'s stock price today?
The current price of ENTX is $2.28. The 52 week high of ENTX is $2.79 and 52 week low is $1.41.
When is next earnings date of Entera Bio Ltd(ENTX)?
The next earnings date of Entera Bio Ltd(ENTX) is 2025-05-09 Est..
Does Entera Bio Ltd(ENTX) pay dividends? If so, how much?
Entera Bio Ltd(ENTX) does not pay dividend.
Guru Commentaries on NAS:ENTX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers